Evidence map›Paper›PMID 30596173›Full record

ArticleKidney international reports2019

Soluble ST2 and Galectin-3 and Progression of CKD.

Mariam L Alam, Ronit Katz, Keith A Bellovich, Zeenat Y Bhat, Frank C Brosius, Ian H de Boer, Crystal A Gadegbeku, Debbie S Gipson, Jennifer J Hawkins, Jonathan Himmelfarb and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Galectin-3: action and clinical utility in chronic kidney disease.International urology and nephrology · 2024
    Review
  13. Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Mariam L AlamDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Ronit KatzDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Keith A BellovichDepartment of Medicine, St. John Hospital Medical Center, Detroit, Michigan, USA.
Zeenat Y BhatDepartment of Medicine, Wayne State University, Detroit, Michigan, USA.
Frank C BrosiusDepartment of Medicine, University of Arizona, Tucson, Arizona, USA.
Ian H de BoerDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Crystal A GadegbekuDepartment of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Debbie S GipsonDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Jennifer J HawkinsDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Jonathan HimmelfarbDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Bryan R KestenbaumDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Matthias KretzlerDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Cassianne Robinson-CohenDepartment of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
Susan P SteigerwaltDepartment of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Courtney TuegelDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Nisha BansalDepartment of Medicine, University of Washington, Seattle, Washington, USA.
University of Washington · USUniversity of Michigan–Ann Arbor · USSt. John Hospital & Medical Center · USTemple University · USUniversity of Arizona · USVanderbilt University · USWayne State University · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
University of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C · 2008 to 2022
$12.9M
Heart failure and atrial arrhythmias in CKDR01DK103612 · NIDDK · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA · 2015 to 2018
$1.9M
Cardiac biomarkers and risk of heart failure and progression of kidney disease in patients with chronic kidney diseaseR03DK102452 · NIDDK · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA · 2015 to 2016
$155k
NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK081943NIDDK NIH HHS R01 DK103612NIDDK NIH HHS R03 DK102452
6 · The paper itself

Abstract

introductionCardiac biomarkers soluble ST2 (sST2) and galectin-3 may reflect cardiac inflammation and fibrosis. It is plausible that these mechanisms may also contribute to the progression of kidney disease. We examined associations of sST2 and galectin-3 with kidney function decline in participants with chronic kidney disease (CKD).

methodsThis was a pooled analysis of 2 longitudinal cohorts of participants with CKD: the Clinical Phenotyping and Resource Biobank (C-PROBE) study and the Seattle Kidney Study (SKS). We measured circulating concentrations of sST2 and galectin-3 at baseline. Our primary outcome was progression to estimated glomerular filtration rate (eGFR) <15 ml/min per 1.73 m

resultsAmong the 841 participants in the pooled cohort, baseline eGFR was 51 ± 27 ml/min per 1.73 m

conclusionHigher concentrations of the cardiac biomarker galectin-3 may be associated with progression of CKD, highlighting potential novel mechanisms that may contribute to the progression of kidney disease.

Indexed as

CKDgalectin-2sST2

Identifiers

PMID30596173
PMCPMC6308819
OpenAlexW2893718882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.